Efficacy and Safety of Fruquintinib Plus PD-1 Inhibitors Versus Regorafenib Plus PD-1 Inhibitors in Refractory Microsatellite Stable Metastatic Colorectal Cancer

Overview of attention for article published in Frontiers in oncology, October 2021

Altmetric Badge

Mentioned by

twitter: 1 X user

Citations

dimensions_citation: 21 Dimensions

Readers on

mendeley: 13 Mendeley

Summary X Dimensions citations

So far, Dimensions has found 21 publications that cite this research output.

21

The most recent citing publications are shown below. View all 21 publications that cite this research output on Dimensions.

Efficacy and safety of hepatic arterial infusion chemotherapy combined with fruquintinib and tislelizumab for patients with microsatellite stable colorectal cancer liver metastasis following failure of multiple-line therapy

Article in Frontiers in Oncology (August 2024)

Efficacy comparison of fruquintinib, regorafenib monotherapy or plus programmed death-1 inhibitors for microsatellite stable metastatic colorectal cancer

Article in World Journal of Gastrointestinal Oncology (June 2024)

Effectiveness of immune checkpoint inhibitors in combination with tyrosine kinase inhibitors in patients with advanced or metastatic colorectal carcinoma with either mismatch repair proficient or metastatic microsatellite stable disease: A systematic review and meta‑analysis

Article in Oncology Letters (February 2024)

This page shows the most recent citations of this research output.

Click here to find out how to access more activity.